Yahoo
NasdaqCM - Delayed Quote USD

IRIDEX Corporation (IRIX)

0.7000 -0.0007 (-0.10%)
At close: September 4 at 4:00:01 PM EDT
0.7000 0.0000 (0.00%)
After hours: September 4 at 7:19:26 PM EDT
Chart Range Bar
Loading chart for IRIX
  • Previous Close 0.7007
  • Open 0.7000
  • Bid 0.5047 x 100
  • Ask 0.9155 x 100
  • Day's Range 0.6910 - 0.7159
  • 52 Week Range 0.6900 - 1.6500
  • Volume 72,838
  • Avg. Volume 66,290
  • Market Cap (intraday) 12.185M
  • Beta (5Y Monthly) 0.63
  • PE Ratio (TTM) --
  • EPS (TTM) -0.2000
  • Earnings Date Nov 17, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 2.75

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. In addition, it offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform transscleral laser therapy; G-Probe and G-Probe Illuminate, which are used in procedures to treat uncontrolled and refractory glaucoma; and EndoProbe family of products that are used for endophotocoagulation. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics through direct and independent sales force in the United States, as well as through independent distributors internationally. It operates in the United States, Europe, the Middle East, Africa, the Asia/Pacific region, and the Americas. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.

www.iridex.com

93

Full Time Employees

January 03

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 9/4/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

IRIX
38.60%
S&P 500 (^GSPC)
12.75%

1-Year Return

IRIX
46.97%
S&P 500 (^GSPC)
18.71%

3-Year Return

IRIX
60.89%
S&P 500 (^GSPC)
70.93%

5-Year Return

IRIX
90.14%
S&P 500 (^GSPC)
70.18%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue 11.8M
Earnings -524k
Profit Margin -4.44%

Q3

FY25

Q4

FY25

Q1

FY26

0
5M
10M
-12.0%
-10.0%
-8.0%
-6.0%
-4.0%
-2.0%

Analyst Insights

View More

Analyst Price Targets

2.75
2.75 Average
0.7000 Current
2.75 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 5/15/2024
Analyst Stifel
Rating Action Maintains
Rating Hold
Price Action Maintains
Price Target 2 -> 2

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (5yr expected)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -6.88%

  • Return on Assets (ttm)

    -5.90%

  • Return on Equity (ttm)

    -73.15%

  • Revenue (ttm)

    51.57M

  • Net Income Avi to Common (ttm)

    -3.55M

  • Diluted EPS (ttm)

    -0.2000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    4.68M

  • Total Debt/Equity (mrq)

    110.28%

  • Levered Free Cash Flow (ttm)

    1.64M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: